Related Experiment Videos
A new strategy for the reduction of acute myocardial infarction in variant angina
Insights
Early revascularization significantly reduces cardiac events in variant angina pectoris patients. This study compared calcium antagonists, nicorandil/nitroglycerin, and percutaneous transluminal coronary angioplasty (PTCA), finding PTCA most effective.
Area of Science:
- Cardiology
- Vascular Medicine
Background:
- Variant angina pectoris requires effective treatment strategies to minimize cardiac events.
- Hospitalization is often necessary for patients with variant angina pectoris.
Purpose of the Study:
- To evaluate the impact of stepwise early treatment on cardiac event frequencies in variant angina pectoris.
- To compare the efficacy of different treatment modalities including medication and revascularization.
Main Methods:
- A study of 159 hospitalized patients with variant angina pectoris.
- Comparison of three treatment groups: calcium antagonists, nicorandil/nitroglycerin infusion, and percutaneous transluminal coronary angioplasty (PTCA).
- Analysis of cumulative cardiac event rates at 1 and 3 years post-treatment.
Main Results:
- The overall cardiac event rate was 16% (25/159 patients).
- Cumulative cardiac event rates at 1 and 3 years were 22% and 23% for calcium antagonists, 11% for nicorandil/nitroglycerin, and significantly lower at 6% for PTCA.
- Stepwise early treatment demonstrated varying efficacy in preventing cardiac events.
Conclusions:
- Early revascularization, specifically PTCA, is crucial for managing variant angina pectoris.
- Combining fast-acting coronary vasodilators with early revascularization improves patient outcomes.
- Treatment strategies should prioritize interventions that reduce long-term cardiac event rates.
Abstract:
To study the effects of stepwise early treatment in variant angina pectoris, frequencies of cardiac events and complications were examined after three different types of treatment. The subjects of the study consisted of 159 consecutive patients with variant angina pectoris, who were in need of hospitalization. The three treatment modalities were the introduction of calcium antagonists, nicorandil and nitroglycerin infusion, and percutaneous transluminal coronary angioplasty (PTCA), respectively. The cardiac event rate for this series of patients was 16% (25 of 159). The cumulative cardiac event rate was 22% at 1 year and 23% at 3 years in the first treatment period; 11% at the same intervals in the second treatment period; and 6% at the same intervals in the third treatment period. Our results suggest that it is important in the treatment of variant angina pectoris not only to prevent anginal attacks by the use of fast-acting coronary vasodilators, but also to initiate early revascularization.